Cervantes, Phrillyn N.
HRN: 20-86-86 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/21/2023
01/27/2023
IV
135mg
Q24
HAP
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes